Quantcast

Industry news that matters to you.  Learn more

Clinical Advantages of Critical Diagnostics’ Cardiac Biomarker ST2 Featured In YouTube Video

Critical Diagnostics, makers of the Presage® ST2 Assay, recently announced that a six-minute videotape by Antoni Bayes-Genis, MD PhD., head of Cardiology Service at Hospital Germans Trias i Pujol, in Barcelona Spain discussing results of a study just completed on the use of biomarkers over conventional clinical assessments for risk stratification of heart failure patients has been posted on YouTube for immediate viewing.

The study followed 876 heart failure patients with a mean age of 70.3 years for a period of 40 months. During this follow up period, 311 patients died. Researchers compared 11 clinical variables, including age, sex, ischemic etiology of heart failure, left ventricular ejection fraction, New York Heart Association functional class, diabetes, renal function, beta blocker treatment, ace inhibitor treatment, sodium and hemoglobin biomarkers, which are routinely used to stratify heart failure risk against three biomarkers: NT-proBNP from Roche (OTC: RHHBY), high-sensitivity troponin T and Critical Diagnostics’ ST2.

The results from this recent study highlights the enduring clinical utility of ST2 despite being combined with the established and widely accepted cardiac biomarkers, like NTpro BNP, in medical practice. “The best results were obtained for ST2 and high-sensitivity troponin T,” notes Dr. Bayes-Genis, the primary investigator of the study. “Whenever we added NT-proBNP to these other two biomarkers, net reclassification improvement was reduced.”

Check out the video below.

“We are seeing strong adoption of ST2 by leading cardiologists who understand many of the limitations of utilizing natriuretic peptide markers like BNP and NT-proBNP in their practice,” states David Geliebter, CEO of Critical Diagnostics. “Natriuretic peptide markers certainly have their role in diagnosing heart failure, but fall short in guiding treatment of diseased patients. In study after study, ST2 has consistently demonstrated improved accuracy of patient prognosis over natriuretic peptide markers alone.

“Two of the biggest criticisms we hear about natriuretic peptide markers are that their levels don’t change or change too slowly, so their value as a serial marker for guiding treatment is questionable and, furthermore, that results are often skewed by other influencers such as age, gender, body mass index, atrial fibrillation, history of heart failure, anemia and impaired renal failure. By comparison, ST2 levels change rapidly in response to changes in the patient’s condition—sometimes within hours—thus helping physicians make informed decisions on an appropriate course of action to take and, if needed, to quickly adjust care, such as titrating medication. Moreover, unlike natriuretic peptide markers, ST2 levels are not adversely affected by the above-mentioned confounding factors.”

“Heart failure has become a growing public epidemic, with increasing incidence and prevalence,” Dr. Bayes-Genis stresses. “As a result, there is a need to understand risk factors and risk stratifiers, to better identify the patients that are going to have a better or a worse outcome. We now have a new generation of biomarkers, high-sensitivity troponin T and ST2, which are easily measurable in our routine practice, which provide additional information to stratify the prognosis of patients with heart failure.”

Source: Critical Diagnostics

Two Major Reference Labs Sign With Critical Diagnostics

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases and Quest Diagnostics (NYSE: DGX) and its subsidiary Berkeley HeartLab, announced recently an agreement under which both Quest and Berkeley HeartLab will offer ST2 testing services based on Critical Diagnostics’ Presage ST2 Assay. Critical Diagnostics has also signed an agreement with Laboratory Corporation of America (NYSE: LH), better known as LabCorp, to offer testing of the Presage ST2 Assay. Combined, these two diagnostic market leaders perform some one-and-a-half million tests per day.

Panel of Biomarkers Proves Useful in Predicting Chronic Heart Failure Outcomes

Critical Diagnostics, a biomarker company focused on cardiovascular diseases, recently announced positive results from a multi-center study in ambulatory heart failure patients, which confirmed that a contemporary panel of biomarkers, including ST2, was strongly predictive of risk and significantly improved the likelihood of identifying patients at risk for adverse events, compared to the most commonly used clinical risk score in heart failure, the Seattle Heart Failure Model (SHFM). The paper (“Multiple Biomarkers for Risk Prediction in Chronic Heart Failure”) was published online in Circulation: Heart Failure on February 23, 2012.

Intrinsic Bioprobes Launches Three New CLIA Approved Mass Spectrometry-based Tests for Proteins Implicated in Kidney Disease and Renal Failure

Intrinsic Bioprobes Inc (“IBI”) today announced the launch of its first
mass spectrometry-based protein assays for in-vitro diagnostic testing. The assays for beta-2-microglobulin, cystatin C, and retinol binding protein are performed on IBI’s MASSAY platform at the CLIA-certified and College of American Pathology (CAP) accredited diagnostic laboratory of the Institute of Genomics Medicine, UMDNJ-New Jersey Medical School.

Discovery and Validation of 13 Diabetes Biomarkers to be Commercialized

After three years of collaborative research involving patients from The Busselton Health Study, drug discovery company Proteomics International announced the identification and analytical validation of 13 protein biomarkers for a significant complication of diabetes – diabetic nephropathy (kidney disease). In a presentation at the Human Proteome Organisation’s World Congress in Sydney, Australia, Dr Richard Lipscombe, Managing Director of Proteomics International, revealed the findings that could benefit many of the 250 million people worldwide who have diabetes.